Iminoral 50 Capsule contains Ciclosporin 50mg, an immunosuppressive agent primarily used to prevent organ transplant rejection and to treat various autoimmune disorders. Ciclosporin exerts its effect by selectively inhibiting the activation of T-lymphocytes, thereby suppressing the immune response. This mechanism is crucial in reducing the risk of graft rejection in kidney, liver, and heart transplant recipients. Additionally, Iminoral 50 is indicated in the management of autoimmune conditions such as rheumatoid arthritis, psoriasis, and certain cases of nephrotic syndrome. The drug is administered orally, with dosage individualized based on patient response, underlying condition, and therapeutic drug monitoring to maintain optimal blood levels and minimize toxicity. Common adverse effects include nephrotoxicity, hypertension, tremors, hyperlipidemia, and increased susceptibility to infections. Regular monitoring of renal function, blood pressure, and ciclosporin blood concentrations is essential during therapy. Caution is advised when co-administered with other nephrotoxic or immunosuppressive agents due to potential additive effects. Iminoral 50 should be used under strict medical supervision, with adherence to prescribed dosing schedules to ensure efficacy and safety. Patient education on potential side effects and the importance of compliance is critical for successful treatment outcomes.